Improvement of cardiac diastolic function and prognosis after autologous peripheral blood stem cell transplantation in AL cardiac amyloidosis

Internal Medicine

Volumn 46, Issue 20, 2007, Pages 1705-1710

  Yagi, Shusuke ^a   Akaike, Masashi ^a   Ozaki, Shuji ^a   Moriya, Chikako ^a   Takeuchi, Kyoto ^a   Hara, Tomoko ^a   Fujimura, Mitsunori ^a   Sumitomo, Yuka ^a   Iwase, Takashi ^a   Ikeda, Yasumasa ^a   Aihara, Ken Ichi ^a   Kimura, Takehiko ^b   Nishiuchi, Takeshi ^b   Abe, Masahiro ^a   Matsumoto, Toshio ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b Kawashima Cardiovascular Clinic   (Japan)

Author keywords

AL cardiac amyloidosis; Autologous peripheral blood stem cell transplantation; Cardiac diastolic function; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; CD34 ANTIGEN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN;

ADULT; ANEMIA; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BLOOD ANALYSIS; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CASE REPORT; CONGESTIVE HEART FAILURE; DIASTOLIC DYSFUNCTION; DRUG MEGADOSE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FIRST DEGREE ATRIOVENTRICULAR BLOCK; HEART AMYLOIDOSIS; HEART LEFT VENTRICLE HYPERTROPHY; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HOLTER MONITORING; HUMAN; IMAGE ANALYSIS; IMMUNOELECTROPHORESIS; LOW DRUG DOSE; MULTIPLE MYELOMA; PATIENT REFERRAL; PROGNOSIS; AMYLOIDOSIS; CARDIOMYOPATHY; HEART; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION;

AMYLOIDOSIS; CARDIOMYOPATHIES; COMBINED MODALITY THERAPY; FEMALE; HEART; HUMANS; MELPHALAN; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS;

EID: 35748959703     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.46.0142     Document Type: Article

References (26)

1. Bellotti V, Merlini G. Current concepts on the pathogenesis of systemic amyloidosis. Nephrol Dial Transplant 11 Supple 9: 53-62, 1996.
2. Kyle RA. Amyloidosis. Circulation 91: 1269-1271, 1995.
3. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 337: 898-909, 1997.
4. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 32: 45-59, 1995.
5. Gertz MA, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Kyle RA. Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol 17: 262-267, 1999.
6. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 336: 1202-1207, 1997.
7. Kyle RA, Greipp PR, Garton JP. Gertz MA. Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine. Am J Med 79: 708-716, 1985.
8. Wardley AM, Jayson GC, Goldsmith DJ, Venning MC, Ackrill P, Scarffe JH. The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone. Br J Cancer 78: 774-776, 1998.
9. Dhodapkar MV, Jagannath S, Vesole D, et al. Treatment of AL-amyloidosis with dexamethasone plus alpha interferon. Leuk Lymphoma 27: 351-356, 1997.
10. Gertz MA, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Kyle RA. Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis. Med Oncol 16: 104-109, 1999.
11. Cueto-Garcia L, Reeder GS, Kyle RA, et al. Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol 6: 737-743, 1985.
12. Klein AL, Hatle LK, Taliercio CP, et al. Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study. Circulation 83: 808-816, 1991.
13. Gertz MA, Kyle RA. Amyloidosis: prognosis and treatment. Semin Arthritis Rheum 24: 124-138, 1994.
14. Gertz MA, Kyle RA. Phase II trial of recombinant interferon alfa-2 in the treatment of primary systemic amyloidosis. Am J Hematol 44: 125-128, 1993.
15. Gertz MA, Kyle RA, Greipp PR. Response rates and survival in primary systemic amyloidosis. Blood 77: 257-262, 1991.
16. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335: 91-97, 1996.
17. Mollee PN, Wechalekar AD, Pereira DL, et al. Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome. Bone Marrow Transplant 33: 271-277, 2004.
18. Dispenzieri A, Lacy MQ, Kyle RA, et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Chn Oncol 19: 3350-3356, 2001.
19. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 140: 85-93, 2004.
20. Gono T, Matsuda M, Shimojima Y, et al. VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese experience and criteria for patient selection. Amyloid 11: 245-256, 2004.
21. Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 104: 1881-1887, 2004.
22. Sanchorawala V, Wright DG, Seldin DC, et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 28: 637-642, 2001.
23. Comenzo RL, Vosburgh E, Falk RH, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 91: 3662-3670, 1998.
24. Moreau P, Leblond V, Bourquelot P, et al. Prognostic factors for survival and. response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 101: 766-769, 1998.
25. Gertz MA, Lacy MQ, Gastineau DA, et al. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant 26: 963-969, 2000.
26. Dispenzieri A, Kyle RA, Lacy MQ, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 103: 3960-3963, 2004.